fda compounding semaglutide enforcement news today 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our GLP-1 Medications – FDA Guidance

The unique form of effervescent tablets ensures 100% solubility

HPLC and MS/MS verified per batch with third-party COA available

Who Benefits Most From Low-Dose GLP-1 Therapy Patients with obesity-related genetic predispositionssuch as variants in the FTO gene or MC4R genemay see meaningful weight loss even at microdoses because their metabolic challenges are being directly addressed

196,197 Such studies have identified a low-frequency variant of CD300LG that is associated with fasting high-density lipoprotein cholesterol (HDL-C), 198 and a TBC1D4 variant that together are connected to higher fasting glucose levels and reduced insulin sensitivity